Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership

Mereo Biopharma Group Plc (MREO) has shared an announcement.

Mereo BioPharma Group plc has partnered with key underwriters for a public offering of 12.5 million American Depositary Shares at $3.99 each, representing five ordinary shares per ADS. The company anticipates a net gain of roughly $45.9 million after expenses and expects the offering to close by June 17, 2024. This move is backed by a shelf registration statement with the SEC, and the underwriters are provided with customary indemnification rights. A recent press release details the offering’s pricing, underscoring the company’s proactive disclosure to investors.

Find detailed analytics on MREO stock on TipRanks’ Stock Analysis page.